Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
0.977
-0.003 (-0.34%)
At close: Jun 26, 2026, 4:00 PM EDT
0.997
+0.020 (2.06%)
After-hours: Jun 26, 2026, 7:37 PM EDT
Company Description
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union.
The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Onconetix, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | David White |
Contact Details
Address: 201 East Fifth Street, Suite 1900 Cincinnati, Ohio 45202 United States | |
| Phone | 513 620 4101 |
| Website | onconetix.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001782107 |
| CUSIP Number | 68237Q401 |
| ISIN Number | US68237Q4010 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Allan White C.A., C.P.A., ICD.D | Chief Executive Officer |
| Karina M. Fedasz | Interim Chief Financial Officer |
| Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Theodore Scott Yoho | Head of Business Development |
| Dr. Ali I. Fattom Ph.D. | Head of Science and Discovery |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2026 | 425 | Filing |
| Jun 17, 2026 | 424B3 | Prospectus |
| Jun 16, 2026 | EFFECT | Notice of Effectiveness |
| Jun 9, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 19, 2026 | 8-K | Current Report |
| May 14, 2026 | 8-K | Current Report |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 424B3 | Prospectus |
| May 11, 2026 | EFFECT | Notice of Effectiveness |
| May 7, 2026 | EFFECT | Notice of Effectiveness |